GHK-Cu 100mg Copper Peptide
GHK-Cu — USA Made, ≥99% Purity
4.9 177 verified reviews- 100mg copper-peptide research format supplied as lyophilized powder
- USA manufactured in GMP-certified California and Arizona laboratory facilities
- ≥99% purity target with third-party HPLC, mass spectrometry, and combined batch COA
For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.
Specifications
- CAS
- 89030-95-5
- Molecular mass
- 402.92 g/mol
- Purity target
- ≥99% (3rd-Party HPLC Tested)
- Form
- Lyophilized Powder
- Origin
- Manufactured, Formulated & Packaged in CA/AZ, USA
- Storage
- Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light
What is GHK-Cu?
GHK-Cu is a copper complex formed by the three-amino-acid peptide Gly-His-Lys and a copper ion. Researchers study this small complex because it combines a defined peptide ligand with biologically relevant copper-coordination chemistry.
Cell and tissue models have examined GHK-Cu in extracellular-matrix turnover, fibroblast signaling, gene-expression changes, and oxidative-stress pathways. The 100mg vial is a laboratory research format and should not be confused with a finished cosmetic or approved drug product.
How It Works
Binds and carries copper: The histidine-centered GHK structure coordinates Cu²⁺ for controlled copper-peptide research.
Influences matrix signaling: Laboratory studies have reported changes in collagen-related activity, matrix metalloproteinases, and extracellular-matrix remodeling.
Modulates cellular responses: Researchers continue to examine gene-expression, antioxidant, and inflammatory signaling associated with the complex.
Why Source from 321 Peptides?
Lot history 3 released lots
Every batch released under this compound, with the figure reported for each.
| Lot | Reported | Purity | Net content | COA |
|---|---|---|---|---|
| GH-50595 Superseded | 2026-04-30 | 99.58% | 100.00 mg | Pending |
| GH-51749 Superseded | 2026-04-23 | 99.49% | 100.20 mg | Pending |
| GH-51172 Superseded | 2026-02-25 | 99.83% | 100.10 mg | Pending |